UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...
Check here for live weather updates and to see active weather alerts, power outages and closings in real time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results